Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BUZZ-U.S. Stocks on the Move-Kamada, Mitek, Stereotaxis, Shoe Carnival

Thu, 04th Sep 2014 14:12

(For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for more market insights,including options activity, ; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s)

U.S. stocks opened slightly higher on Thursday, after theEuropean Central Bank cut interest rates to record lows and aflurry of economic data indicated the U.S. economy was steadilyimproving. The Dow Jones industrial average was up 0.37percent at 17,141.44, the S&P 500 was up 0.40 percent at2,008.66 and the Nasdaq Composite was up 0.2 percent4,581.71.

** SHOE CARNIVAL INC, $19.635, -11.39 pct

The footwear retailer reported lower-than-expected secondquarter sales and profit as fewer customers visited its storesand expenses rose. Its profit has now missed estimates for thelast three quarters. The company forecast third quartercomparable-store sales to either decline up to 1 percent or growup to 1 percent.

Susquehanna Financial Group analysts cut price target to $24from $25 on the stock which had fallen 24 percent this year upto Wednesday's close.

** SOLARCITY CORP, $71.3, +5.29 pct

The solar panel installer said it would open 20 newoperations centres in seven U.S. states. The company, backed byTesla Motors Inc founder Elon Musk, says new centersexpected to create more than 600 additional jobs.

** BAZAARVOICE INC, $8.09, +7.87 pct

B. Riley & Co raises price target on stock of the softwaremaker to $10 from $9.75, saying net new client additions in Q1were significantly higher than it had estimated.

Bazaarvoice, which provides businesses online and socialmedia tools to interact with customers, reportedhigher-than-expected Q1 revenue and smaller-than-expected losson Wednesday

** VERIFONE SYSTEMS INC, $35.93, +4.02 pct

The credit card swipe machine maker raised full-year revenueforecast for the third time, encouraged by strong sales ofdevices that can accept chip-embedded credit cards. VeriFonealso raised full-year profit forecast and reportedbetter-than-expected third quarter revenue.

The company is benefiting as U.S. retailers upgrade theirpoint-of-sale terminals to systems compatible with more securecredit cards in the wake of several data breaches. Up toWednesday's close, the stock had risen nearly 30 percent thisyear.

** ARLINGTON ASSET INVESTMENT CORP, $27.14, -4.40 pct

The mortgage investor said it was offering 2.75 millionshares of Class A common stock - 14 percent of its totaloutstanding shares - at $27.61 each, a 2.7 pct discount toWednesday's close.

Arlington said it plans to use the proceeds to acquireassets. Up to Wednesday's close, the stock had risen 7.6 percentthis year.

** STEREOTAXIS INC,$3.31, +16.14 pct

The medical device maker received U.S. FDA's marketingapproval for its device used during procedures to assess heartactivity. The device, called Vdrive Robotic Navigation System,is designed to remotely control catheter during such procedures.

** KAMADA LTD, $5.6, -21.79 pct

The Israel-based drugmaker's experimental drug to treat aninherited condition that raises the risk of lung and liverdisease failed in a mid-stage study. The drug, Inhaled Alpha-1Antitrypsin, did not show a statistically significantdifference, compared with a placebo. Glassia, an intravenousversion of the drug, is already being marketed by Baxter Inc in the United States.

** CIENA CORP, $19.13, -6.50 pct

The network equipment forecast fourth quarter revenue of$570 million-$610 million, below the average analyst estimate of$628.9 million. The company said it expects fourth quarteradjusted gross margin in the high 30s to low 40s percent range.

** MITEK SYSTEMS INC, $3.46, +45.99 pct

The mobile imaging software maker agreed on Wednesday tosettle all pending litigation with financial services group USAAover five of its patents relating to image capture on mobiledevices. Mitek's lawsuit filed in 2012 also included allegationsof misappropriation of trade secrets, breach of contract andfraud. The company said neither party will make any payment oradmit liability on any claims.

** GOPRO INC, $54.865, -3.51 pct

J.P. Morgan cut its rating on the stock of the maker of camera makers to "neutral" from "overweight", saying the stockis trading above its price target of $51. The median pricetarget on stock is $46.50. Of nine analysts covering the stock,2 have "buy" ratings and 7 have "hold" or equivalent ratings. Upto Wednesday's close, the stock had risen 137 percent since itsdebut on June 26.

** MEMORIAL PRODUCTION PARTNERS LP, $22.28, -3.80pct

The oil and gas producer said it would offer 13 millioncommon units; representing 18 percent of outstanding shares asof Wednesday. The company said it plans to use net proceeds fromthe underwritten public offering to pay down debt.

** MATTRESS FIRM HOLDING CORP, $63.443, +11.68 pct

The company said it would buy privately held beddingretailer The Sleep Train Inc for $425 million, its sixth andlargest acquisition announced in the past year, to expand itspresence on the West Coast.

** NEWLINK GENETICS CORP, $26.73, +2.93 pct

NewLink Genetics said the U.S. Food and Drug Administrationallowed the company to start testing an experimental Ebolavaccine in humans.

The move follows a decision to begin initial human testingof a GlaxoSmithKline vaccine this month and an approvalto fast track tests of a Johnson & Johnson vaccine.

** TIBCO SOFTWARE INC, $22, +4.56 pct

The business software maker said it was reviewing itsstrategic and financial alternatives as part of a processinitiated by its board on Aug. 16 to maximize shareholder value. The company has formed a special committee of independentdirectors to undertake the review.

** MATRIX SERVICE CO, $22.29, -23.48 pct

The engineering and construction services provider's fourthquarter revenue and profit missed analysts' estimates due to a47 percent rise in costs. Revenue from the company's oil, gasand chemical segment, which provides construction andmaintenance services to North American oil producers, fell about22 percent to $52.1 million. Matrix also forecast full-yearearnings below estimates.

** PVH CORP, $127.74, +9.06 pct

The apparel company's second quarter profit beatexpectations, helped by strong sales of its TommyHilfiger-branded clothes. PVH cut its full-year revenue forecastto $8.4 billion from $8.5 billion, but it reaffirmed its profitforecast.

** JOY GLOBAL INC, $61.56, -1.03 pct

The mining equipment maker posted lower-than-expectedquarterly revenue and profit and the company narrowed itsfull-year earnings forecast range as coal miners cut spendingdue to weak coal prices amid an oversupply. (Compiled by Rohit T.K. in Bangalore; Editing by Joyjeet Das)

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.